MannKind Corporation (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix ReadyFlow™, the first and only autoinjector designed to deliver IV-equivalent diuretic therapy for treating edema in adults with heart failure or chronic kidney disease (CKD). The device offers patients an at-home treatment option that may reduce the need for hospital-based intravenous therapy. Alongside the regulatory milestone, MannKind also announced a $50 million private placement (PIPE) priced at $3.89 per share. The financing is expected to support the commercial launch of Furoscix ReadyFlow and strengthen the company's financial position. Sector: Biotechnology / Healthcare Key Highlights: ✅ FDA approved Furoscix ReadyFlow™, the first autoinjector delivering IV-equivalent diuretic therapy 💉 Indicated for treating edema in adults with heart failure or chronic kidney disease 🏠 Enables convenient at-home administration, reducing reliance on hospital IV treatment 💰 Announced a $50 million PIPE financing at $3.89 per share 📈 Funding will support commercialization and future business growth initiatives Why It Matters The FDA approval expands MannKind's commercial portfolio with an innovative treatment designed to improve patient convenience and care. Combined with the new capital raise, the company is better positioned to support the product launch and accelerate its growth strategy. https://www.thinksabio.com/reports/isr/MNKD